

## **Dicot has identified several new patent opportunities**

**Press release: Uppsala, February 21, 2022. Dicot announces that the company is strengthening its IP assets by identification and documentation of ten new patent opportunities as a result of the company's work to maximize shareholder value.**

As a developing pharmaceutical company, Dicot follows a pronounced partnering strategy with a plan to out-license the company's drug candidate LIB-01 with data from clinical phase 2 studies. To maximize shareholder value from future out-licensing deals, the company works with a strong patent strategy to offer future licensees the longest possible market exclusivity via the company's patents.

Dicot's patent portfolio holds two granted patent families on key pharmaceutical markets, placing Dicot in a strong position and provides Dicot market exclusivity for LIB-01 until 2033.

Dicot now announces that ten new patent opportunities have been captured and documented. These new assets mean that Dicot has the opportunity to extend the patent protection of the company's drug candidate by 20 years after patent applications have been filed. That would mean extended patent protection until at least 2042.

To ensure maximum value from investments in patents, these assets are now controlled as trade secrets in order to be converted into patents at the right point of time. This ensures the longest possible patent life and value optimization.

“Dicot's IP portfolio is already a unique asset on the multi-billion pharmaceutical market for sexual dysfunction and we are committed to continue strengthening our IP portfolio and these new IP assets secure great long term value”, says Göran Beijer, CEO at Dicot.

### **For further information, please contact:**

Göran Beijer CEO  
Tel: +46 706 63 60 09  
Email: [goran.beijer@dicot.se](mailto:goran.beijer@dicot.se)

### **About Dicot AB**

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit [www.dicot.se](http://www.dicot.se).

---